Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment

Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into the next phase of clinical and corporate catalysts. …